Stock MYNZ MAINZ BIOMED N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Real-time Estimate Cboe BZX
Other stock markets
 01:39:55 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.713 USD -10.65% Intraday chart for Mainz Biomed N.V. -18.55% -39.05%
May. 07 Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week CI
Apr. 25 Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
EQ
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
GL
Mainz Biomed Reports Results of 2024 Annual General Meeting
GL
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
EQ
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
GL
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
GL
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
EQ
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
GL
Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week
CI
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQ
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
GL
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
CI
Mainz Biomed N : Announcement of Annual General Meeting of - Form 6-K
PU
Mainz Biomed Reports Full Year 2023 Financial Results
EQ
Mainz Biomed Reports Full Year 2023 Financial Results
GL
Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
EQ
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
GL
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
AQ
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYNZ Stock
  4. News Mainz Biomed N.V.